Press Releases Camurus AB

Equities

CAMX

SE0007692850

Real-time Estimate Cboe Europe Other stock markets 10:59:26 2024-04-29 am EDT			5-day change	1st Jan Change
496.5 ^SEK	+1.33%		+4.25%	-7.96%

Apr. 17	Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
Apr. 02	Camurus AB Announces Board Resignations	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notice of annual general meeting 2024 in Camurus (publ)	Apr. 02	AQ
Camurus Annual Report for 2023	Mar. 28	AQ
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	Mar. 05	AQ
Camurus' Full Year Report 2023	Feb. 15	AQ
Camurus appoints Behshad Sheldon as President of Camurus Inc.	Feb. 13	AQ
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease	Feb. 08	AQ
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million	Jan. 17	AQ
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023	Jan. 17	AQ
Change in number of shares and votes in Camurus	Dec. 29	AQ
Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly	Dec. 21	AQ
Camurus to enter Large Cap segment on Nasdaq Stockholm	Dec. 20	AQ
Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors	Dec. 14	AQ
Camurus' Interim Report Third Quarter 2023	Nov. 09	AQ
Camurus : receives improved ESG risk rating by Sustainalytics	Nov. 05	PU
Camurus to present at Jefferies 2023 Healthcare Conference London	Nov. 01	AQ
Camurus raises financial guidance for the full year 2023	23-10-23	AQ
Camurus' Nomination Committee appointed for the Annual General Meeting 2024	23-10-18	AQ
Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund	23-09-26	AQ
Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn	23-09-05	AQ
Change in number of shares and votes in Camurus	23-08-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Camurus AB

Equities

CAMX

SE0007692850

Press Releases

Filters